# Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor

> **NCT05933668** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 11 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** YK0901 cells

## Key facts

- **NCT ID:** NCT05933668
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07
- **Primary completion:** 2024-07
- **Final completion:** 2026-07
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933668, "Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05933668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*